Helicobacter pylori infection in Greenlandic patients with dyspepsia.
OBJECTIVE
The aim was to evaluate the incidence of Helicobacter pylori (HP) infection in Greenland, to assess the value of the test "Helicobacter antigen in faeces" as a diagnostic tool and to determine the level of antibiotic resistance.


METHODS
100 consecutive patients with dyspepsia who visited for endoscopic gastric examination were included. The patients had to be born in Greenland and to be > or = 18 years old.


METHODS
Samples for HP antibody in blood, HP antigen in faeces, urease test on biopsies were collected from the patients. Gastric biopsies were cultured for HP bacteria, and antibiotic resistance was tested. Patients with positive urease test and/or antigen in faeces and/or positive culture were treated simultaneously with Amoxicillin, Metronidazole and Esomeprazole for 1 week. Patients with duodenal or gastric ulcer were endoscopically re-examined 8 weeks later. Patients with proven HP infection but without ulcer submitted a faeces sample 8 weeks after the eradication.


RESULTS
77 patients were considered HP infected, and received treatment. Only 32% of them were eradicated sufficiently.


CONCLUSIONS
HP antigen in faeces test is useful as a diagnostic tool and for control of therapy. A change in strategy of HP treatment in Greenland is a must, presumably preceded by an elucidation of microbial sensitivity.
Johansen
Jens Kurt
JK
Surgical Department, Dronning Ingrids Hospital, Greenland. jk.johansen@wanadoo.dk
Sehested
Ane
A
Myrhøj
Torben
T
Ladefoged
Karin
K
Krogfelt
Karen A
KA
D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004415:Dyspepsia / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D064098:Esomeprazole / Q000627:therapeutic use; D006116:Greenland / Q000453:epidemiology; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D000658:Amoxicillin; D064098:Esomeprazole